Catalogo Ricerca Università di Cagliari

Catalogo Ricerca Università di Cagliari: [109020] Home page macrotipologia

Sfoglia

1 Contributo su Rivista 60663
- 1.1 Articolo in rivista 56082
- 1.2 Recensione in rivista 1712
- 1.3 Scheda bibliografica 116
- 1.4 Nota a sentenza 872
- 1.5 Abstract in rivista 1777
- 1.6 Traduzione in rivista 105

2 Contributo in Volume 18390
- 2.1 Contributo in volume (Capitolo o Saggio) 16183
- 2.2 Prefazione/Postfazione 599
- 2.3 Breve introduzione 247
- 2.4 Voce (in dizionario o enciclopedia) 904
- 2.5 Traduzione in volume 149
- 2.6 Recensione in volume 36
- 2.7 Schede di catalogo 272

3 Libro 3084
- 3.1 Monografia o trattato scientifico 2732
- 3.2 Concordanza 3
- 3.3 Indice 5
- 3.4 Bibliografia 16
- 3.5 Edizione critica 90
- 3.6 Pubblicazione di fonti inedite 19
- 3.7 Commento scientifico 19
- 3.8 Traduzione di libro 200

4 Contributo in Atti di Convegno (Proceeding) 21312
- 4.1 Contributo in Atti di convegno 15682
- 4.2 Abstract in Atti di convegno 4385
- 4.3 Poster 1245

5 Altro 1783
- 5.01 Composizione 2
- 5.02 Disegno 12
- 5.03 Design 15
- 5.04 Performance 36
- 5.05 Esposizione 20
- 5.06 Mostra 45
- 5.07 Manufatto 2
- 5.08 Prototipo d'arte e relativi progetti 3
- 5.09 Cartografia 136
- 5.10 Banca dati 61
- 5.11 Software 12
- 5.12 Altro 1366
- 5.13 Progetto architettonico 73

6 Brevetti 208
- 6.1 Brevetto 208

7 Curatele 1607
- 7.1 Curatela 1607

8 Tesi di Dottorato 1976
- 8.1 Tesi di Dottorato 944
- 8.2 Tesi di dottorato (ePrints) 1032

Prodotti recenti

A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals

Purpose: We conducted a comprehensive analysis of esketamine-related adverse events (AE) on the FDA Adverse Event Reporting System (FAERS) database, taking into account for the first time drug-drug interaction signals. Methods: We conducted a retrospective case/non-case study of esketamine-related AEs reported in the FAERS database up to the last quarter (Q4) of 2024. Potential signals were detected using the reporting odds ratio (ROR) and confidence intervals (CI), while drug-drug interactio...

Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

Background: We recently published the first real-world multicenter and multi-institutional study of cisplatin, gemcitabine, and durvalumab in patients with advanced biliary tract cancer (BTC). Here we present an expanded patient cohort with an increased sample size and longer median follow-up. Methods: The study population included patients with advanced BTC, who received cisplatin/gemcitabine plus durvalumab at 55 centers across 12 countries in Europe, the United States, and Asia. The primar...

The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

Background: Cisplatin, gemcitabine, and durvalumab combination is a standard first-line treatment for advanced biliary tract cancer. This study aimed to assess the impact of genetic alterations on outcomes in patients with advanced biliary tract cancer treated with cisplatin, gemcitabine, and durvalumab in real-world clinical practice. Methods: Patients with unresectable, locally advanced, or metastatic biliary tract cancer treated with cisplatin and gemcitabine plus durvalumab across 39 cent...

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection

Background International guidelines recommend 5FU/LV, Nal-IRI + 5FU/LV, FOLFIRI, FOLFOX, or (m)FOLFIRINOX as second-line (2L) chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after failure of gemcitabine+Nab-paclitaxel (GnP). However, a head-to-head comparison has not been performed. Patients and methods We conducted an observational cohort study of consecutive mPDAC patients treated with 2L chemotherapy after GnP failure at 41 Italian centers. Progression-fr...

Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study

Background: Diabetes mellitus (DM) is a known risk factor for pancreatic ductal adenocarcinoma (PDAC). Preclinical evidence suggests higher glucose levels may enhance chemotherapy injury to PDAC cells. Clinical evidence of DM's impact in patients with PDAC receiving palliative treatment remains conflicting, however. Materials and methods: PANCAKE, an Italian multicenter observational study, assessed the impact of DM and blood glucose levels on progression-free survival during first-line treat...

Scopri

Accesso al fulltext

no fulltext65290
reserved22713
open18727
partially open2040
embargoed143
mixed90
restricted17

UNICA IRIS Institutional Research Information System